vildagliptin
AssetSmall moleculeAlso LAF237, Vildagliptin (LAF237), Vildagliptin/ Metformin, vildagliptin + metformin
Dipeptidyl peptidase-4 (DPP-4) inhibitor preventing degradation of incretin hormones
- Stage
- Approved
- Modality
- Small molecule
- Target
- AMPK signalling
- Indications
- 11
- Trials
- 1,452
- Developers
- 1
Indications
11Diabetes
Approvedema.europa.eu7 Oct 2026
Type 2 diabetes
Approvedema.europa.eu7 Oct 2026
Acromegaly
Phase 3COMPLETEDNCT02060383clinicaltrials.gov7 Oct 2026
8 more
- Targets and what it contains6
- Owner and partners1
- Trials1,452
- Evidence for its targets6
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 19 sources